The Effect of 2nd generation TKI on the outcome after allogeneic SCT for Patients with CML: A Non-Interventional Prospective Study
Patient Inclusion closes October 1st, 2013
As the study is nearing its recruitment target of 390 patients, it has been decided to close the study for patient inclusion per 01 October 2013.
What does this mean?
- eligible patients of participating centres who receive their allogeneic transplant after 01 October 2013 cannot enter the study.
- eligible patients of participating centres who receive their allogeneic transplant before 01 October 2013 should still be registered in the study.
It is mandatory for participating centres to register all their consecutive eligible patients in the study.
Therefore we urge all participating centres to verify whether all their eligible patients
from 01 January 2010 onwards have been registered in the study.
Participating centres will have until 31 December 2013 to register their eligible patients from the study period. Patient registration forms should be sent to the data office as soon as possible; study data can be submitted at a later point in time during the study.
Patient inclusion criteria
All adult patients with chronic myeloid leukemia in any phase (chronic, accelerated or blastic) who undergo any type of allogeneic stem cell transplantation and have been previously treated with Nilotinib or Dasatinib, regardless of their response to this TKI.
Eligible patients received their allogeneic transplant between 01 January 2010 and 30 September 2013.
For more information about the study, please contact Jennifer Hoek, study coordinator at the EBMT Data Office in Leiden, via email@example.com
Call for data
The chart below shows that although most patients have been registered in the database, the submission of MED B/C and follow up data for this study is not up to expectation. Therefore we want to ask all participants to update their patients in the study at the earliest convenience, and…
Please, do not forget to send in your patients’ MED C form!
We would like to thank all participants for their ongoing cooperation in this important study!
CML subcommittee of the CMWP.